Marek Widera
- Infectious Diseases top 1%
- Molecular Biology top 10%
- Immunology top 10%
- Biomedical Engineering top 10%
- Epidemiology top 10%
- Co-authors
- Sandra CiesekDenisa BojkováJindřich ČinátlBenjamin KochKevin KlannChristian MünchDavid KrauseSandra Westhaus
- Topics
- SARS-CoV-2 and COVID-19 Research (27 papers)HIV Research and Treatment (19 papers)COVID-19 Clinical Research Studies (15 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Marek Widera
71 papers receiving 2.2k citations
Hit Papers
Peers
Comparison fields: 5 of 104
- Infectious Diseases 1.4k
- Molecular Biology 703
- Immunology 338
- Biomedical Engineering 332
- Epidemiology 266
Countries citing papers authored by Marek Widera
This map shows the geographic impact of Marek Widera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Widera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Widera more than expected).
Fields of papers citing papers by Marek Widera
This network shows the impact of papers produced by Marek Widera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Widera. The network helps show where Marek Widera may publish in the future.
Co-authorship network of co-authors of Marek Widera
This figure shows the co-authorship network connecting the top 25 collaborators of Marek Widera. A scholar is included among the top collaborators of Marek Widera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marek Widera. Marek Widera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 38 | |
| 3 | 15 | |
| 4 | 10 | |
| 5 | 14 | |
| 6 | 4 | |
| 7 | 5 | |
| 8 | 1 | |
| 9 | 43 | |
| 10 | 9 | |
| 11 | 25 | |
| 12 | Proteomics of SARS-CoV-2-infected host cells reveals therapy targetsbreakdown → | 642 |
| 13 | 34 | |
| 14 | 265 | |
| 15 | 3 | |
| 16 | 10 | |
| 17 | 8 | |
| 18 | 10 | |
| 19 | 54 | |
| 20 | 2 |
About Marek Widera
Marek Widera is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 71 papers that have together received 2.2k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (27 papers), HIV Research and Treatment (19 papers) and COVID-19 Clinical Research Studies (15 papers). The work is most often cited by research in Infectious Diseases (1.4k citations), Virology (240 citations) and Immunology (338 citations). Marek Widera has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Sandra Ciesek, Denisa Bojková, Jindřich Činátl, Benjamin Koch, Kevin Klann, Christian Münch, David Krause, Sandra Westhaus, Heiner Schaal and Tuna Toptan. Their work appears in journals such as Nature, Nucleic Acids Research and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.